Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
18 authors.
Soravis OsataphanDivision of Hematology and Hematologic Malignancies, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.ORCID 0000-0002-6503-4418
Rushad PatellDivision of Hematology and Hematologic Malignancies, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.ORCID 0000-0002-8426-3398
Mrigya BabutaDivision of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.ORCID 0000-0001-8420-4796
Rachel P RosovskyDivision of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-2392-7365
Yohei HisadaUNC Blood Research Center, Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.ORCID 0000-0001-9157-0524
Charly EdmistonDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.ORCID 0009-0009-6086-1674
Pavania ElavalakanarDivision of Hematology and Hematologic Malignancies, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.ORCID 0000-0001-6754-8095
Michael A PfefferDivision of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-1758-5442
Amy BregarDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-6593-1573
Amanda RamosDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Leslie GarrettDivision of Gynecologic Oncology, Department of Obstetric and Gynecology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.ORCID 0000-0003-1712-909X
Siyang RenDivision of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
Donna NeubergDivision of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0003-2566-3145
Gyongyi SzaboDivision of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.ORCID 0000-0003-0836-2527
Robert FlaumenhaftDivision of Hematology and Hematologic Malignancies, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.ORCID 0000-0001-8004-9688
Nigel MackmanUNC Blood Research Center, Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.ORCID 0000-0002-9170-7700
Meghan SheaDivision of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.ORCID 0000-0002-7419-6654
Jeffrey I ZwickerHematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0001-5810-6893
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The efficacy of rosuvastatin to reduce circulating tissue factor extracellular vesicles after ovarian cancer surgery. · full record | OpenQuestion